Quantcast

Latest Epoetin beta Stories

2011-12-23 08:58:26

Anemia drugs prevent many transplanted kidneys from failing Correcting anemia, a red blood cell deficiency, can preserve kidney function in many kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results indicate that aggressively treating anemia may help save the kidneys–and possibly the lives–of many transplant recipients. Anemia commonly arises in patients with kidney disease...

2009-11-11 16:58:54

Use of erythropoiesis-stimulating agents is associated with an increased risk of venous thromboembolism, according to study published online November 10 in the Journal of the National Cancer Institute. Erythropoiesis-stimulating agents (i.e., erythropoietin and darbopoietin) stimulate red blood cell production and therefore were approved to reduce the number of blood transfusions required during chemotherapy; however, concerns about the risks of venous thromboembolism (the disease that...

2009-05-05 07:47:44

Cancer patients find themselves in a sort of catch-22 situation when it comes to treating the anemia common in people with the disease. While drugs called erythropoiesis-stimulating agents (ESAs) can cut down on the need for blood transfusions and improve quality of life, they have also been associated with serious adverse events like heart attacks and strokes and may even promote tumor growth. Now a new study out of Germany is quantifying the problem. Researchers there pooled data from 53...

2009-05-02 07:31:43

Erythropoiesis-stimulating agents not recommended as routine therapy The use of drugs to encourage red blood cell formation (erythropoiesis-stimulating agents) in cancer patients with anemia increases the risk of death and serious adverse events such as blood clots, found a new study in CMAJ. While the relative increased risk of death was only 15-16%, because of the high mortality rates in cancer patients this increase might translate into significant numbers of people. "These findings...

2008-11-07 12:00:23

Affymax, a biopharmaceutical company, has announced positive results from a long-term safety and effectiveness study of its lead investigational therapy, Hematide, which is being evaluated for the treatment of anemia in chronic renal failure patients. In the Phase II study, 182 patients using Hematide once every four weeks for up to 23 months successfully maintained average hemoglobin levels within an 11 to 12g/dl target range. A retrospective analysis of 115 patients from a Phase II...

2008-11-04 12:00:26

Affymax, a biopharmaceutical company, has completed enrollment in the second of four Phase III clinical trials of its lead investigational therapy, Hematide, which is being evaluated for the treatment of anemia in chronic renal failure patients. The Phase III evaluation of Hematide for anemia correction in chronic renal failure (Pearl 2) is fully enrolled with over 490 non-dialysis patients from over 60 sites in the US and Europe. The Hematide Phase III program, involving a total of...

2008-06-30 09:03:37

Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has begun in a Phase 2 clinical trial of Hematide(TM) to correct anemia in patients with chronic renal failure (CRF) who are undergoing dialysis and are not actively being treated with an erythropoiesis stimulating agent (ESA). The trial is intended to generate data for Hematide as an anemia correction therapy in this segment of the CRF patient population, some of whom may be ESA-naive. This is the first Hematide correction study in...

2007-03-07 09:00:29

By Cornes, Paul; Coiffier, Bertrand; Zambrowski, Jean-Jacques Key words: Anemia - Blood transfusion - Cost effectiveness - Epoetin - Pharmacoeconomics ABSTRACT Background: Healthcare organizations must evaluate the cost effectiveness of the alternative therapies that are available to treat anemia and improve quality of life (QoL) of patients with cancer, that is, erythropoietic protein therapy and blood transfusion. Methods: Pharmacoeconomic studies that evaluated the cost of not...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.